Can low levels of taurine make stillbirth more likely?

Tommy’s researchers are looking at how the lack of an important nutrient might harm the placenta during pregnancy, putting women at a higher risk of stillbirth.

  • Authors list

    Dr Michelle Desforges, Professor Alexander Heazell, Susan Greenwood, Professor Colin Sibley

Start: August 2015

End: April 2019

Why is this research needed?

When a baby is stillborn, it is often not possible to say why. This can be very distressing for the family. Not only have they suffered the loss of their baby; no one can give them a reason for their pain.

That’s why Tommy’s want to find answers that will not only help us understand why babies are stillborn, but will stop this happening in the future.

Scientists think that one reason may be the placenta not getting enough of an important nutrient: taurine.

What’s happening with this project?

Taurine is essential for our bodies, because the mitochondria – the parts of our cells that make energy – need taurine to work. Our researchers think that if cells in the placenta don’t have enough taurine, our mitochondria can’t make enough energy, and the cells will die.

We also know that the placentas of obese pregnant women cannot take up as much taurine as women with a healthy weight. This may contribute to the higher risk of stillbirth faced by obese women.

Tommy’s researchers are looking at placentas donated by both obese and non-obese women to see if too little taurine can lead to damage to the placenta. From this, they hope to find out if measuring the amount of taurine in the placenta can be used as a test to predict pregnancy complications and stillbirth.

So far, our researchers have been studying the role of taurine in protecting the cells in placentas from damage. The team have done experiments to show that reducing taurine in samples of placenta interferes with how cells protect themselves from damage.

What impact could this project make?

The role of mitochondria in stillbirth is an exciting new area of research that hasn’t been studied before. This project will help us to understand how damage to the placenta can lead to stillbirth, so families can find the answers they need. We can use this knowledge to find new ways of telling when women are at risk, and possibly new treatments that could help stop stillbirths from happening in the future

More research projects

  • Research into stillbirth

    When a baby dies after 24 weeks of gestation, it is called a stillbirth. Nearly 3000 families a year get the devastating news that their baby is not alive. Our research is helping to change this.
    Research into stillbirth

  • Diabetes, fetal growth and stillbirth

    Women suffering from type 1 or type 2 diabetes are more likely to suffer from stillbirths. We want to help people with diabetes to have healthy pregnancies.
    Diabetes, fetal growth and stillbirth

  • Preventing stillbirth: the role of the immune system in rejecting the placenta

    Tommy’s are studying chronic histiocytic intervillositis, which causes the immune system to reject the placenta, leading to stillbirth or miscarriage.
    Preventing stillbirth: the role of the immune system in rejecting the placenta

  • Understanding how the womb lining matures during pre-eclampsia

    Pre-eclampsia can lead to health problems and sometimes stillbirth, but we don’t know enough about what causes it. Our researchers are studying how the lining of the womb develops during early pregnancy. This could reveal new ways to prevent pre-eclampsia and reduce the risk of stillbirth.
    Understanding how the womb lining matures during pre-eclampsia

  • The AFFIRM trial for prevention of stillbirth

    Researchers supported by Tommy’s are looking at whether a package of care and resources for pregnant women can help stop stillbirths.
    The AFFIRM trial for prevention of stillbirth

  • Homing peptides: targeting drugs to the placenta

    Drugs which could help prevent pregnancy complications can’t reach the placenta effectively. Tommy’s researchers are making use of ‘homing peptides’ to deliver drugs directly to the placenta. This work could help to prevent pregnancy complications and stillbirth.
    Homing peptides: targeting drugs to the placenta

  • Stillbirth and fetal free haemoglobin

    Researchers supported by Tommy’s have found that the substance that usually carries oxygen around our blood may have harmful effects on the baby when it escapes from red blood cells.
    Stillbirth and fetal free haemoglobin

  • ReMIT-2 – a feasibility study for spotting the early signs of complications

    We need better ways to spot the early signs of pregnancy complications. The ReMIT-2 study laid the foundations for a large clinical trial of a blood test which could predict which women need urgent care to prevent stillbirth.
    ReMIT-2 – a feasibility study for spotting the early signs of complications

Tommy’s new and views